{"URL": "https://www.wired.com/1999/07/tailor-made-meds", "heading": "tailor-made meds", "subheading": "genetics as researchers around the globe slog onward decoding the human genome gene by gene and promising tangible results within a decade or so, a new jersey biotech startup is building an online database of genetic info that will make personalized medicines a reality within three years. orchid biocomputer, based in princeton, is one of [\u2026]", "author": "kristen philipkoski", "category": "not found", "type": "article", "timestamp": "07.01.1999 12:00 PM", "text": "geneticsas researchers around the globe slog onward decoding the human genome gene by gene and promising tangible results within a decade or so, a new jersey biotech startup is building an online database of genetic info that will make personalized medicines a reality within three years. orchid biocomputer, based in princeton, is one of a few dozen companies studying genetic mutations known as snps (pronounced \"snips\") - single nucleotide polymorphisms.these small variations in the genome determine how different individuals will react to a drug, and who is predisposed to, say, alzheimer's. \"many drugs never make it through clinical development, since they cause adverse effects in a small number of patients,\" says dale pfost, orchid's president and ceo. \"the side effects could be avoided if patients were genetically subtyped before treatment.\"while most players have focused solely on identifying the millions of possible snps, orchid is taking the next step: snp scoring - determining the real-world implications of genetic variations. what your doctor prescribes for your allergies, for instance, will depend on your genetic makeup.orchid's megasnpatron scoring facility opens this fall and will offer the highest throughput in the world; by 2000, it will analyze more than 1 million snps a day. starting this summer, the company is making its data available to the public. patients can order a blood-test kit from orchid, mail a sample, and subscribe to the company's ongoing news service. as snps are scored and their health implications understood, the company will report its findings to subscribers.with a growing list of research institutions providing snps, orchid simply plans to keep on scoring.must readsputterniktired/wiredgood dealas the well turnsall's well that ends wellsmarter bombbattlefield of tomorrowpass it onfashion policewhy buy retail?paranoia technologytailor-made medspeoplejargon watchpersonality typingcustomize or diesailing the red skiesgrubstake grillt1, good buddyraw data"}